Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Early Hemoglobin kinetics in response to ribavirin: Safety lesson learned from Hepatitis C to CoVID-19 therapy

Antonio Rivero-Juarez, Mario Frias, Isabel Machuca, Marina Gallo, Pedro Lopez-Lopez, Angela Camacho, Antonio Rivero
doi: https://doi.org/10.1101/2020.06.29.20142281
Antonio Rivero-Juarez
aInfectious Diseases Unit. Hospital Universitario Reina Sofía de Córdoba. Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC). University of Cordoba. Cordoba, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mario Frias
aInfectious Diseases Unit. Hospital Universitario Reina Sofía de Córdoba. Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC). University of Cordoba. Cordoba, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Isabel Machuca
aInfectious Diseases Unit. Hospital Universitario Reina Sofía de Córdoba. Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC). University of Cordoba. Cordoba, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marina Gallo
aInfectious Diseases Unit. Hospital Universitario Reina Sofía de Córdoba. Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC). University of Cordoba. Cordoba, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pedro Lopez-Lopez
aInfectious Diseases Unit. Hospital Universitario Reina Sofía de Córdoba. Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC). University of Cordoba. Cordoba, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angela Camacho
aInfectious Diseases Unit. Hospital Universitario Reina Sofía de Córdoba. Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC). University of Cordoba. Cordoba, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonio Rivero
aInfectious Diseases Unit. Hospital Universitario Reina Sofía de Córdoba. Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC). University of Cordoba. Cordoba, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ariveror@gmail.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Ribavirin (RBV) is been used for SARS-CoV-2 infection. This drug is associated with a wide range of side effects, mainly anemia, so its use in patients with potential respiratory affectation could not be appropriate. The evidences of adverse events associated with RBV-use has mainly been derived in the context of hepatitis C (HCV) treatment, however the possible use of RBV in CoVID-19 patients could be limited to 14 days.

Methods Longitudinal study including HIV/HCV coinfected patients. We evaluate the hemoglobin dynamics and reductions as well as evaluate the development rate of anemia during the first 2 weeks of therapy in HCV infected patients.

Results 189 patients were included in the study. The median hemoglobin levels were 14.6 g/dL (IQR: 13.2-15.6 g/dL) and 13.5 g/dL (IQR: 12.3-14.5 g/dL) at weeks 1 and 2 of therapy, respectively. A cumulative number of 27 (14.2%) patients developed anemia (23 grade 1 [12.1%] and 4 grade 2 [2.1%]). We identify a baseline hemoglobin levels of 14 g/dL as the better cut-off to identify those patients with a high chance to develop anemia. Of the 132 patients with baseline hemoglobin level >14 g/dL, 8 developed anemia (6.1%) compared with 19 of 57 (33.3%) with hemoglobin levels lower than 14 g/dL (p < 0.001).

Conclusions Our study shows valuable information about the early hemoglobin kinetic timing in patients on RBV-therapy, that could be useful to tailor CoVID-19 treatment if RBV use is considered.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by the Ministerio de Sanidad (RD12/0017/0012) integrated in the Plan Nacional de I+D+I and cofinanced by the ISCIII-Subdireccion General de Evaluacion and the Fondo Europeo de Desarrollo Regional (FEDER). ARJ is the recipient of a Miguel Servet Research Contract by the Ministerio de Ciencia, Promocion y Universidades of Spain (CP18/00111). MF is the recipient of a Sara Borrell contract by the Ministerio de Ciencia, Promocion y Universidades of Spain (CD18/00091).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was designed and performed according to the Declaration of Helsinki. All patients provided written informed consent before included in the cohort. The study was approved by the Comite de Etica de Investigacion de Cordoba (D439/2010). All patients signed an Informed consent form in writing that gave permission to store and process their samples in the Biobanco del Hospital Universitario Reina Sofia de Cordoba (ISCIII reference: B.0000419), which is integrated into the Biobanco del Sistema Sanitario Publico de Andalucia, as well as to use of their clinical data for research.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Raw data is available under reasonable request to corresponding author

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted June 29, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Early Hemoglobin kinetics in response to ribavirin: Safety lesson learned from Hepatitis C to CoVID-19 therapy
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Early Hemoglobin kinetics in response to ribavirin: Safety lesson learned from Hepatitis C to CoVID-19 therapy
Antonio Rivero-Juarez, Mario Frias, Isabel Machuca, Marina Gallo, Pedro Lopez-Lopez, Angela Camacho, Antonio Rivero
medRxiv 2020.06.29.20142281; doi: https://doi.org/10.1101/2020.06.29.20142281
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Early Hemoglobin kinetics in response to ribavirin: Safety lesson learned from Hepatitis C to CoVID-19 therapy
Antonio Rivero-Juarez, Mario Frias, Isabel Machuca, Marina Gallo, Pedro Lopez-Lopez, Angela Camacho, Antonio Rivero
medRxiv 2020.06.29.20142281; doi: https://doi.org/10.1101/2020.06.29.20142281

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Toxicology
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (168)
  • Anesthesia (49)
  • Cardiovascular Medicine (448)
  • Dentistry and Oral Medicine (80)
  • Dermatology (55)
  • Emergency Medicine (157)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (190)
  • Epidemiology (5218)
  • Forensic Medicine (3)
  • Gastroenterology (195)
  • Genetic and Genomic Medicine (750)
  • Geriatric Medicine (77)
  • Health Economics (212)
  • Health Informatics (694)
  • Health Policy (352)
  • Health Systems and Quality Improvement (223)
  • Hematology (98)
  • HIV/AIDS (162)
  • Infectious Diseases (except HIV/AIDS) (5823)
  • Intensive Care and Critical Care Medicine (356)
  • Medical Education (102)
  • Medical Ethics (25)
  • Nephrology (80)
  • Neurology (758)
  • Nursing (43)
  • Nutrition (129)
  • Obstetrics and Gynecology (141)
  • Occupational and Environmental Health (231)
  • Oncology (475)
  • Ophthalmology (149)
  • Orthopedics (38)
  • Otolaryngology (94)
  • Pain Medicine (39)
  • Palliative Medicine (19)
  • Pathology (139)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (136)
  • Primary Care Research (96)
  • Psychiatry and Clinical Psychology (854)
  • Public and Global Health (1994)
  • Radiology and Imaging (345)
  • Rehabilitation Medicine and Physical Therapy (157)
  • Respiratory Medicine (283)
  • Rheumatology (93)
  • Sexual and Reproductive Health (72)
  • Sports Medicine (75)
  • Surgery (108)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)